Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 21.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,847 shares of the company’s stock after selling 5,407 shares during the period. SG Americas Securities LLC’s holdings in Pacira BioSciences were worth $374,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after buying an additional 2,749 shares during the last quarter. CWM LLC raised its holdings in shares of Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after purchasing an additional 5,716 shares during the period. Virtus Investment Advisers Inc. purchased a new position in shares of Pacira BioSciences in the 3rd quarter worth about $98,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Pacira BioSciences by 62.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock worth $134,000 after purchasing an additional 3,404 shares during the period. Finally, Quest Partners LLC raised its holdings in shares of Pacira BioSciences by 137.6% during the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock valued at $142,000 after buying an additional 5,449 shares during the period. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $25.75 on Tuesday. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -12.68 and a beta of 0.80. The stock’s fifty day simple moving average is $20.23 and its 200-day simple moving average is $17.68.

Wall Street Analysts Forecast Growth

PCRX has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a report on Wednesday, December 4th. Barclays reduced their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Needham & Company LLC lifted their target price on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Pacira BioSciences has an average rating of “Hold” and an average price target of $26.20.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.